OmniAb (OABI) EBITDA Margin (2022 - 2026)
OmniAb (OABI) posted quarterly EBITDA Margin of 54.27% for Q1 2026, up 39937.0% year-over-year from N/an in Q1 2025, and up 71.17% quarter-over-quarter from 188.23% in Q4 2025.
Powered by 
Analysis
OmniAb (OABI) EBITDA Margin (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported EBITDA Margin for 5 consecutive years, with 54.27% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 39937.0% year-over-year to 54.27%; the TTM figure through Mar 2026 stood at 200.26% (up 6444.0% YoY), while the FY2025 annual figure was 369.49%, down 8719.0% from the prior year.
- EBITDA Margin advanced to 54.27% in Q1 2026 per OABI's latest filing, from 188.23% in the prior quarter.
- Across five years, EBITDA Margin topped out at 25.6% in Q4 2022 and bottomed at 810.18% in Q3 2025.
- Historically, EBITDA Margin has averaged 290.67% across 5 years, with a median of 215.76% in 2022.
- Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 54338 bps — and 2026, when it surged 39937 bps.
- OmniAb's EBITDA Margin stood at 25.6% in 2022, then slumped by 1818 bps to 439.78% in 2023, then jumped by 67 bps to 146.98% in 2024, then slipped by 28 bps to 188.23% in 2025, then surged by 71 bps to 54.27% in 2026.
- Business Quant data shows OABI's EBITDA Margin at 54.27% in Q1 2026, 188.23% in Q4 2025, and 810.18% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | OmniAb | 560.26 Mn | 508.26 Mn | 12.81 Mn | -49.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.47% |
| Mar 31, 2026 | -54.27% |
| Dec 31, 2025 | -188.23% |
| Sep 30, 2025 | -810.18% |
| Jun 30, 2025 | -416.19% |
| Mar 31, 2025 | -453.64% |
| Dec 31, 2024 | -146.98% |
| Sep 30, 2024 | -473.73% |
| Jun 30, 2024 | -214.14% |
| Mar 31, 2024 | -593.34% |
| Dec 31, 2023 | -439.78% |
| Sep 30, 2023 | -370.91% |
| Jun 30, 2023 | -279.95% |
| Mar 31, 2023 | -49.96% |
| Dec 31, 2022 | 25.60% |
| Sep 30, 2022 | -215.76% |
| Jun 30, 2022 | -174.55% |
| Mar 31, 2022 | -85.45% |